Literature DB >> 3552594

Current status of postmenopausal oestrogen therapy.

R L Young, J W Goldzieher.   

Abstract

Mesh：

Substances：

Year:  1987        PMID： 3552594     DOI： 10.2165/00003495-198733020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  34 in total

1.  Systemic absorption and sustained effects of vaginal estrogen creams.

Authors:  P L Martin; S S Yen; A M Burnier; H Hermann
Journal:  JAMA       Date:  1979-12-14       Impact factor: 56.272

2.  Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens.

Authors:  S B Baumgardner; H Condrea; T A Daane; J H Dorsey; H N Jurow; J P Shively; M Wachsman; L R Wharton; M J Zibel
Journal:  Obstet Gynecol       Date:  1978-04       Impact factor: 7.661

3.  Estrogen use and cardiovascular disease.

Authors:  B E Henderson; R K Ross; A Paganini-Hill; T M Mack
Journal:  Am J Obstet Gynecol       Date:  1986-06       Impact factor: 8.661

4.  Biologic effects of various doses of ethinyl estradiol in postmenopausal women.

Authors:  F P Mandel; F L Geola; J K Lu; P Eggena; M P Sambhi; J M Hershman; H L Judd
Journal:  Obstet Gynecol       Date:  1982-06       Impact factor: 7.661

5.  Effects of estrogen therapy on vaginal physiology during menopause.

Authors:  J P Semmens; C C Tsai; E C Semmens; C B Loadholt
Journal:  Obstet Gynecol       Date:  1985-07       Impact factor: 7.661

6.  Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women.

Authors:  A L Magos; M Brincat; J W Studd; P Wardle; P Schlesinger; T O'Dowd
Journal:  Obstet Gynecol       Date:  1985-04       Impact factor: 7.661

7.  Micronized 17 beta-estradiol for oral estrogen therapy in menopausal women.

Authors:  M R Callantine; P L Martin; O T Bolding; P O Warner; M O Greaney
Journal:  Obstet Gynecol       Date:  1975-07       Impact factor: 7.661

8.  Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17beta-estradiol in postmenopausal women.

Authors:  S S Yen; P L Martin; A M Burnier; N M Czekala; M O Greaney; M R Callantine
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

9.  The effect of ethinyl oestradiol on calcium and bone metabolism in peri- and postmenopausal women.

Authors:  R W Marshall; P L Selby; D C Chilvers; A Hodgkinson
Journal:  Horm Metab Res       Date:  1984-02       Impact factor: 2.936

10.  Sublingual absorption of micronized 17beta-estradiol.

Authors:  A M Burnier; P L Martin; S S Yen; P Brooks
Journal:  Am J Obstet Gynecol       Date:  1981-05-15       Impact factor: 8.661
View more
  5 in total

Review 1.  A risk-benefit appraisal of transdermal estradiol therapy.

Authors:  A Cheang; R Sitruk-Ware; W H Utian
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 2.  Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints.

Authors:  J A Balfour; R C Heel
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Pharmacokinetic evaluation of oral 17 beta-oestradiol and two different fat soluble analogues in ovariectomized women.

Authors:  W Schubert; G Cullberg; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Nasal absorption enhancement of 17 beta-estradiol by dimethyl-beta-cyclodextrin in rabbits and rats.

Authors:  W A Hermens; M J Deurloo; S G Romeyn; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 5.  Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.

Authors:  J A Balfour; D McTavish
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.